ClinicalTrials.gg
CompletedNCT05140928Updated Dec 2, 2021

The Effect of Maternal Dadiah Supplementation During Pregnancy on Child Growth and Gastrointestinal Health Outcomes

An interventional study of Dadiah Pudding and Pudding without Dadiah in Gastrointestinal Microbiome, Immunoglobulin A and Growth; Stunting, Nutritional, sponsored by Andalas University. Completed at 1 site in Indonesia. Open to female participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-02.

Sponsored by Andalas University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2020, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Growth Disorders with a site in Indonesia — 1 open to participants now, 3 under way, none of them phase 3. Growth Disorders · Indonesia.

Enrollment
11th of 11
52 · median 217
Started
2020
with 3 others
No phase
11 of 18
1 open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
Andalas University

Among the 18 studies in Growth Disorders with a site in Indonesia, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2020, is one of 11 with no phase, and was the 13th registered.

Growth Disorders

227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.

Browse Growth Disorders studies →

Open to participants now

1 of the 18 studies in Growth Disorders with a site in Indonesia is open now. Recruiting first, the newest first:

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 18 Growth Disorders studies recruiting now, 3 (17%) set no upper age limit and 13 (72%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 20 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Growth Disorders with a site in Indonesia, or all of them as a file.
02

Study summary

The aim of our study is to assess the effect of giving dadiah as a supplement to pregnant women on improving the growth and digestive health of children.

Read the detailed description

The study was carried out on pregnant women in four Public Health Center (PHC) areas in Padang Panjang, West Sumatra, Indonesia. They were screened for inclusion and exclusion criteria. Once eligibility was confirmed, pregnant women were randomly allocated to intervention or control groups. The details of the study protocol were explained, and voluntary written consent was obtained.

General information about the mother was collected and a general physical examination was assessed. The intervention started at about 10-20 weeks of gestation and continued until just before the time of delivery. Subjects took the study supplements concurrently with the government's dietary supplementation program. In each home visit, the remaining supplements from the previous visit were counted and documented in the pudding checklist form. Details of symptoms or illnesses during consumption of dadiah pudding will be reported either by participants directly contacting field officers, study staff, or during weekly visits and will be recorded and documented in the case report form. In the third trimester, subjects received healthy food, breastfeeding practices, and child development education to support mothers in maintaining their nutritional status, preparing exclusive breastfeeding, and optimizing child development.

Healthy babies born to mothers will be the focus of this study and followed up until the age of three months to assess their growth. The information includes the baby's health history after birth, anthropometric measurements, nutritional intake, and breastfeeding practices which are measured repeatedly in the first, second, and third months. The collection of breast milk and baby feces is carried out in the first week and third month after the baby is born.

The sample size was calculated taking into account all outcome variables including the proportion of gut microbiota, levels of IgA secretion in breast milk and infant feces, and child growth, with the independent variable being maternal supplementation during pregnancy.

Data quality assurance is carried out through training starting from the period of data collection and supervision during and after data collection, including the data analysis process. This included training for enumerators, subjects and using a validated questionnaire for a group of subjects representing similar characteristics for this study. Data input and cleaning process will use excel and SPSS while for food intake data using NutriSurvey 2007. Data entry will be carried out by data collection officers after data collection. The data cleaning process includes removing outliers and regrouping multiple results that have similar meanings. The data will be interpreted as mean ± standard deviation if the data is normally distributed and the median (min-max) if the data is not normally distributed. Statistical analysis using SPSS 20 and data will be analyzed using univariate and bivariate analysis. Univariate analysis is used to describe characteristics and socio-demographics, medical history, pregnancy, and obstetric profiles of pregnant women. Numerical variables between groups will be analyzed using an Independent sample t-test if the data has normal distribution or the Mann Whitney test if the data distribution is not normal. Categorical variables between groups will be analyzed using Chi-square or Fisher test. Differences between birth and 3 months old follow up will be analyzed using Dependent t-tests if the data distribution has normal distribution or Wilcoxon test if the data distribution is not normal.

03

Conditions studied

  • Gastrointestinal Microbiome
  • Immunoglobulin A
  • Growth; Stunting, Nutritional

Browse trials for

Keywords

  • dadiah
  • local yogurt
  • Minangkabau yogurt
  • pregnant women
  • dietary supplement
  • gut microbiota
  • immunoglobulin A
  • gastrointestinal health
  • fermented dairy product
  • lactic acid bacteria
  • child growth
  • probiotic
04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with10-20 weeks gestation
  • Women give voluntary
  • Women willing to give exclusive breastfeeding
  • Women live in an area under study, registered, and visit antenatal care at targeted public health centers
  • Women plan to deliver babies in the area under study

Exclusion criteria

Exclusion Criteria:

  • Women having a medical history of /AIDS, TBC, .
  • Women with multiple pregnancies
  • Women having obesity, and/or another high-risk pregnancy (hypertension, preeclampsia, diabetes, bleeding history)
  • Received antibiotic treatment or intentionally consumes probiotic products during the preceding 4 weeks. (If the subject was on antibiotics before the beginning of the study or probiotics, a of 2 weeks is required.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Dadiah Pudding

    The mother received 1 cup or 100 g dadiah pudding containing 75-gram dadiah which provide ±260 kcal energy, 6.12g protein, 23.31g fat, 6.49g carbohydrate, and 6.1x 109 CFU/ml lactic acid bacteria.

    Other: Dadiah Pudding

  • Placebo comparator
    Pudding without dadiah

    The mother received 1 cup or 100 g pudding without dadiah containing ±75 kcal energy, 0.3g protein, 0.45 g fat, and 16.2g carbohydrate.

    Other: Pudding without Dadiah

Interventions

  • OtherDadiah Pudding

    Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy

    Also known as: Minangkabau Yogurt Pudding

  • OtherPudding without Dadiah

    Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy

    Also known as: Milk Pudding

06

What researchers measure

Primary outcomes

  1. Infant fecal gut microbiota proportion

    Relative difference of non-pathogen and pathogen to total bacteria in infant fecal sample

    Time frame: three months

  2. Breast milk gut microbiota proportion

    Relative difference of non-pathogen and pathogen to total bacteria in infant fecal sample

    Time frame: three months

  3. Level of infant fecal secretory Immunoglobulin A

    Concentration of secretory Immunoglobulin A in infant fecal sample

    Time frame: three months

  4. Level of breastmilk secretory Immunoglobulin A

    Concentration of secretory Immunoglobulin A in breastmilk sample

    Time frame: three months

Secondary outcomes

  1. Weight increment

    Change in body's relative mass of the child measured by subtract child weight at three months old to child weight in the first week

    Time frame: three months

  2. Length increment

    Change in distance from the bottom of the feet to the top of the head in child's body fully extended and feet flexed measured by subtract child weight at three months old to child length in the first week

    Time frame: three months

  3. Head circumferences increment

    Change in the circumference of the distance from above the eyebrows and ears and around the back of the head as a parameter in evaluate nutritional status measured by subtract child head circumference at three months old to child head circumference in the first week

    Time frame: three months

07

Study locations

1 site
  • Zuhrah Taufiqa
    Padang, West Sumatra 25144, Indonesia
08

References and documents

Publications

  • Rinita Amelia, Koshy Philip, Yudha Endra Pratama EP. Characterization and probiotic potential of lactic acid bacteria isolated from dadiah sampled in West Sumatra. Food Sci Technol. 2020
  • Taufiqa Z, Chandra DN, Helmizar H, Lipoeto NI, Hegar B. Micronutrient Content and Total Lactic Acid Bacteria of Dadiah Pudding as Food Supplementation for Pregnant Women. 2021;9:1149-55
  • Collado MC, Surono IS, Meriluoto J, Salminen S. Potential probiotic characteristics of Lactobacillus and Enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization. J Food Prot. 2007 Mar;70(3):700-5. doi: 10.4315/0362-028x-70.3.700. PubMed 17388062 ↗
  • Surono IS. Traditional Indonesian dairy foods. Asia Pac J Clin Nutr. 2015;24 Suppl 1:S26-30. doi: 10.6133/apjcn.2015.24.s1.05. PubMed 26715081 ↗
  • Surono IS, Martono PD, Kameo S, Suradji EW, Koyama H. Effect of probiotic L. plantarum IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children. J Trace Elem Med Biol. 2014 Oct;28(4):465-9. doi: 10.1016/j.jtemb.2014.07.009. Epub 2014 Aug 2. PubMed 25183688 ↗
  • Mantaring J, Benyacoub J, Destura R, Pecquet S, Vidal K, Volger S, Guinto V. Effect of maternal supplement beverage with and without probiotics during pregnancy and lactation on maternal and infant health: a randomized controlled trial in the Philippines. BMC Pregnancy Childbirth. 2018 May 31;18(1):193. doi: 10.1186/s12884-018-1828-8. PubMed 29855271 ↗
  • Robertson RC. The Gut Microbiome in Child Malnutrition. Nestle Nutr Inst Workshop Ser. 2020;93:133-144. doi: 10.1159/000503352. Epub 2020 Jan 28. PubMed 31991429 ↗
  • Swartwout B, Luo XM. Implications of Probiotics on the Maternal-Neonatal Interface: Gut Microbiota, Immunomodulation, and Autoimmunity. Front Immunol. 2018 Dec 3;9:2840. doi: 10.3389/fimmu.2018.02840. eCollection 2018. PubMed 30559747 ↗
  • Chen Y, Li Z, Tye KD, Luo H, Tang X, Liao Y, Wang D, Zhou J, Yang P, Li Y, Su Y, Xiao X. Probiotic Supplementation During Human Pregnancy Affects the Gut Microbiota and Immune Status. Front Cell Infect Microbiol. 2019 Jul 16;9:254. doi: 10.3389/fcimb.2019.00254. eCollection 2019. PubMed 31380297 ↗
  • Baldassarre ME, Di Mauro A, Mastromarino P, Fanelli M, Martinelli D, Urbano F, Capobianco D, Laforgia N. Administration of a Multi-Strain Probiotic Product to Women in the Perinatal Period Differentially Affects the Breast Milk Cytokine Profile and May Have Beneficial Effects on Neonatal Gastrointestinal Functional Symptoms. A Randomized Clinical Trial. Nutrients. 2016 Oct 27;8(11):677. doi: 10.3390/nu8110677. PubMed 27801789 ↗
  • Prakoeswa CRS, Herwanto N, Prameswari R, Astari L, Sawitri S, Hidayati AN, Indramaya DM, Kusumowidagdo ER, Surono IS. Lactobacillus plantarum IS-10506 supplementation reduced SCORAD in children with atopic dermatitis. Benef Microbes. 2017 Oct 13;8(5):833-840. doi: 10.3920/BM2017.0011. Epub 2017 Oct 12. PubMed 29022387 ↗
  • Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10. PubMed 24912386 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2021, 12 months.

Of 77 non-industry interventional studies with no phase under Growth Disorders, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's 12 months is below that.

Counting every sponsor, half of 78 studies reached it within 23 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Dec 2, 2021
StartActual
Aug 20, 2020
Primary completionActual
Sep 9, 2021
CompletionActual
Sep 9, 2021
Last update
Dec 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05140928
Lead sponsor
Andalas University
Responsible party
Zuhrah Taufiqa (Principal Investigator, Andalas University) — Principal investigator
First posted
Dec 2, 2021
Start date
Aug 20, 2020
Primary completion
Sep 9, 2021
Completion
Sep 9, 2021
Last update
Dec 2, 2021

Study contacts

Zuhrah Taufiqa, MD
study director · Indonesia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion